Sangamo Therapeutics Inc (SGMO) VP Edward R. Conner Sells 5,000 Shares

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $18.49, for a total transaction of $92,450.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Edward R. Conner also recently made the following trade(s):

  • On Monday, January 8th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $17.11, for a total transaction of $85,550.00.

Shares of Sangamo Therapeutics Inc (SGMO) traded up $2.45 during midday trading on Wednesday, reaching $22.10. 3,468,748 shares of the company’s stock were exchanged, compared to its average volume of 1,410,000. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. The company has a market cap of $1,870.00, a P/E ratio of -32.03 and a beta of 2.87. Sangamo Therapeutics Inc has a one year low of $3.55 and a one year high of $22.53.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. The company had revenue of $11.81 million for the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. Sangamo Therapeutics’s revenue for the quarter was up 333.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.27) EPS. equities analysts anticipate that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in SGMO. Quantbot Technologies LP bought a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth about $118,000. Amalgamated Bank bought a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth about $158,000. Chicago Equity Partners LLC bought a new stake in shares of Sangamo Therapeutics in the 4th quarter worth about $192,000. Great West Life Assurance Co. Can increased its holdings in shares of Sangamo Therapeutics by 150.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 7,667 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Sangamo Therapeutics by 6.8% in the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 832 shares during the last quarter. Institutional investors own 64.06% of the company’s stock.

SGMO has been the topic of a number of analyst reports. Wedbush restated a “hold” rating and set a $6.00 target price on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. BidaskClub downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Barclays initiated coverage on shares of Sangamo Therapeutics in a report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price target on the stock. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Finally, Piper Jaffray Companies set a $25.00 price target on shares of Sangamo Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 3rd. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Sangamo Therapeutics presently has an average rating of “Buy” and an average price target of $18.83.

WARNING: “Sangamo Therapeutics Inc (SGMO) VP Edward R. Conner Sells 5,000 Shares” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/07/sangamo-therapeutics-inc-sgmo-vp-edward-r-conner-sells-5000-shares.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply